title: Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up.
abstract: BACKGROUND
  Adipokines such as adiponectin and resistin, as well as angiogenin, may be associated with inflammation and atherosclerosis. The relationship between their levels and prognosis in high risk patients is, however, still unclear. The aim of this study was to evaluate the prognostic value of these adipokines in patients with stable multivessel coronary artery disease (MCAD).
  
  
  METHODS
  The study group comprised 107 MCAD patients (74% males, mean age 63 ± 8 years). Adiponectin, resistin and angiogenin plasma levels were measured at admission and after 1-year follow-up. Primary end point (major adverse cardiac and cerebrovascular events--MACCE) was defined as cardiac death, nonfatal myocardial infarction, stroke, and hospitalization for angina or heart failure over a 1-year period.
  
  
  RESULTS
  After 1-year follow-up, 9 (8%) patients died, all from cardiovascular causes. Primary end point was experienced by 32% of patients. Surgical treatment (CABG) was received by 51% of patients, while 49% were treated medically alone. Total cholesterol concentration levels ≥ 173 mg/dl were associated with a 7-fold increase (OR 7.3; 95% CI, 1.6-33.0); LDL ≥ 93.5 mg/dl with a 16-fold increase (OR 16.3; 95% CI, 2.8-93.8), and resistin ≥ 17.265 ng/ml with a 13-fold increase in MACCE risk (OR 13.5; 95% CI, 2.3-80.3). In multivariate analysis, a medical treatment strategy (p = 0.001), a higher CCS class (p = 0.004), resistin levels (p = 0.003) and a higher Gensini score (p = 0.03) were independent predictors of MACCE.
  
  
  CONCLUSIONS
  In stable patients with MCAD, elevated plasma resistin (as opposed to adiponectin or angiogenin) is a strong, independent predictive factor for the occurrence of MACCE over 1-year follow-up.
authors.affiliation: 2nd Department of Cardiology Medical University, Lodz, Poland. rkrecki@gazeta.pl
authors.forename: Radoslaw
authors.initials: R
authors.lastname: Kreçki
authors.forename: Maria
authors.initials: M
authors.lastname: Krzemińska-Pakuła
authors.forename: Jan Z
authors.initials: JZ
authors.lastname: Peruga
authors.forename: Piotr
authors.initials: P
authors.lastname: Szcześniak
authors.forename: Piotr
authors.initials: P
authors.lastname: Lipiec
authors.forename: Karina
authors.initials: K
authors.lastname: Wierzbowska-Drabik
authors.forename: Daria
authors.initials: D
authors.lastname: Orszulak-Michalak
authors.forename: Jarosław Damian
authors.initials: JD
authors.lastname: Kasprzak
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000150:complications*; D004452:Echocardiography; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006323:Heart Arrest / Q000175:diagnosis* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011044:Poland; D011379:Prognosis; D052243:Resistin / Q000097:blood*; D012259:Ribonuclease, Pancreatic / Q000097:blood*; D018709:Statistics, Nonparametric; D020521:Stroke / Q000175:diagnosis* / Q000209:etiology
chemical_list: D052242:Adiponectin; D052243:Resistin; C046366:angiogenin; D012259:Ribonuclease, Pancreatic